CD8A and breast cancer: Similarly, in the breast cancer model, cGAMP (a common STING agonist) treatment activated the STING signal pathway to produce anti-tumor effects, which were impaired by using the anti-CD8 antibody to deplete CD8+ T cells of the tumor microenvironment (46).